Migreen kliinilised uuringud osariigis Colorado
7 uuringut haiguse Migreen jaoks otsivad osalejaid osariigis Colorado.
Linnad osariigis Colorado
Ametlik uuringutekst (inglise keeles)
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Children's Hospital Colorado- Investigational Drug Services, Aurora
- Children's Hospital Colorado, Aurora
VärbamineFaas 3
Vanused 6–17 · Kõik sood · Uuendatud 24. sept 2026 · NCT04743141Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Children's Hospital Colorado- lnvestigational Drug Services, Aurora
- Children's Hospital Colorado, Aurora
VärbamineFaas 3
Vanused 6–17 · Kõik sood · Uuendatud 24. sept 2026 · NCT04649242Puberty, Testosterone, and Brain Development
- Children's Hospital Colorado, Aurora
VärbamineVaatlusuuring
Vanused 12–20 · Kõik sood · Uuendatud 21. sept 2026 · NCT06670053Responding With Evidence and Access for Childhood Headaches
- University of Colorado/Children's Hospital Colorado, Aurora
Värbamine
Vanused 10–17 · Kõik sood · Uuendatud 21. sept 2026 · NCT05889624Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- University of Colorado Anschutz Medical Campus, Aurora
VärbamineFaas 4
Vanused 18–70 · Kõik sood · Uuendatud 16. sept 2026 · NCT06972056Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Paradigm Clinical Research - Aurora, CO /ID# 280612, Aurora
- Children's Hospital Colorado - Aurora /ID# 231879, Aurora
VärbamineFaas 3
Vanused 6–17 · Kõik sood · Uuendatud 14. sept 2026 · NCT05125302A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- IMMUNOe Research Centers, Centennial
- MCB Clinical Research Centers, Colorado Springs
- Advanced Neurosciences Research, Fort Collins
VärbamineFaas 3
Vanused 18–75 · Kõik sood · Uuendatud 20. aug 2026 · NCT07645924Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.